Previous studies demonstrated that S100A9 is frequently upregulated in breast tumors [23–25], and its overexpression is closely associated with metastatic progression [24, 26–29], chemoresistance [34], and poor prognosis of patients with breast cancer [25, 30, 31]. Here, S100A9 is linked to breast carcinoma.